Stockreport

Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints [Yahoo! Finance]

Roivant Sciences Ltd.  (ROIV) 
PDF announced positive results from the Phase 3 VALOR study, a 52-week placebo-controlled trial evaluating the once-daily oral drug brepocitinib in patients with dermatomyos [Read more]